2024 한국형 범불안장애 치료지침 III: 치료 반응이 불충분한 경우 및 공존질환이 존재하는 경우 치료 전략 = Korean Guidelines for the Treatment of Generalized Anxiety Disorder 2024 Part III: Strategies for Insufficient Treatment Response and Comorbidities

다국어 초록 (Multilingual Abstract)

Objective : This study aimed to establish expert consensus on treatment strategies for generalized anxiety disorder (GAD) when treatment response is insufficient and when comorbid conditions are present as part of developing the 2024 Korean guidelines for the treatment of GAD.
Methods : The executive committee developed a questionnaire based on existing international and Korean treatment guidelines and academic literature. Sixty-five experts participated in a survey. Responses were analyzed using chi-squared test and 95% confidence intervals to determine the level of consensus. Treatment strategies were categorized into first-line, second-line, and third-line choices.
Results : For patients with an insufficient treatment response, combining pharmacotherapy and psychotherapy was the most preferred first-line strategy. Experts recommended switching to or augmenting with a different class of antidepressants, adding benzodiazepines or azapirones, and augmenting with atypical antipsychotics as first-line pharmacotherapy adjustments. Suitable psychotherapies included cognitive behavioral therapy (CBT), mindfulness-based cognitive therapy (MBCT), acceptance and commitment therapy (ACT), and applied relaxation. For patients with comorbid conditions such as depression, other anxiety disorders, or alcohol and substance use disorders, a combination of pharmacotherapy and psychotherapy was also the most preferred first-line treatment. In these cases, the use of antidepressants alone or in combination with benzodiazepines, azapirones, or atypical antipsychotics was recommended.
Conclusion : This expert consensus reflects current clinical practices and experiences in Korea, providing valuable insights for clinicians treating GAD patients who have insufficient treatment responses or comorbidities. Findings of this study emphasize the importance of a multimodal treatment approach, including both pharmacotherapy and psychotherapy. They also offer specific recommendations for adjusting treatment strategies in these complex cases. (Anxiety and Mood 2024;20(2):72-81)

참고문헌 (Reference)

1 Lohoff FW, "Ziprasidone treatment of refractory generalized anxiety disorder : a placebocontrolled, double-blind study" 30 : 185-189, 2010

2 Bandelow B, "World Federation of Societies of Biological Psychiatry(WFSBP)guidelines for treatment of anxiety, obsessive-compulsive and posttraumatic stress disorders-version 3. Part I : Anxiety disorders" 24 : 79-117, 2023

3 Bidzan L, "Vortioxetine(Lu AA21004)in generalized anxiety disorder : results of an 8-week, multinational, randomized, double-blind, placebo-controlled clinical trial" 22 : 847-857, 2012

4 Rothschild AJ, "Vortioxetine(Lu AA21004)5 mg in generalized anxiety disorder : results of an 8-week randomized, double-blind, placebo-controlled clinical trial in the United States" 22 : 858-866, 2012

5 Tyrer P, "Thirty-year outcome of anxiety and depressive disorders and personality status : comprehensive evaluation of mixed symptoms and the general neurotic syndrome in the follow-up of a randomised controlled trial" 12 : 1-10, 2021

6 Hettema JM, "The nosologic relationship between generalized anxiety disorder and major depression" 25 : 300-316, 2008

7 Zhu B, "The cost of comorbid depression and pain for individuals diagnosed with generalized anxiety disorder" 197 : 136-139, 2009

8 Andrews G, "Royal Australian and New Zealand College of Psychiatrists clinical practice guidelines for the treatment of panic disorder, social anxiety disorder and generalised anxiety disorder" 52 : 1109-1172, 2018

9 Simon NM, "Quetiapine augmentation of paroxetine CR for the treatment of refractory generalized anxiety disorder : preliminary findings" 197 : 675-681, 2008

10 Katzman MA, "Quetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder : a flexible-dose, openlabel pilot trial" 22 : 1480-1486, 2008

11 Preti A, "Prevalence, impact and treatment of generalised anxiety disorder in bipolar disorder : a systematic review and meta-analysis" 19 : 73-81, 2016

12 De Salas-Cansado M, "Pregabalin versus SSRIs and SNRIs in benzodiazepine-refractory outpatients with generalized anxiety disorder : a post hoc cost-effectiveness analysis in usual medical practice in Spain" 4 : 157-168, 2012

13 Chen TR, "Pharmacological and psychological interventions for generalized anxiety disorder in adults : a network meta-analysis" 118 : 73-83, 2019

14 Snyderman SH, "Open-label pilot study of ziprasidone for refractory generalized anxiety disorder" 25 : 497-499, 2005

15 Pollack MH, "Olanzapine augmentation of fluoxetine for refractory generalized anxiety disorder : a placebo controlled study" 59 : 211-215, 2006

16 Sagliano L, "Non-invasive brain stimulation in generalized anxiety disorder : a systematic review" 93 : 31-38, 2019

17 Baldwin DS, "Lu AA21004, a multimodal psychotropic agent, in the prevention of relapse in adult patients with generalized anxiety disorder" 27 : 197-207, 2012

18 Merikangas KR, "Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication" 64 : 543-552, 2007

19 이준엽 ; 김민숙 ; 이상혁 ; 양종철 ; 김찬형 ; 유범희 ; 서호석, "Korean Medication Algorithm Project for Generalized Anxiety Disorder 2009(II) : medication algorithm & long-term medication treatment strategy" 49 : 553-563, 2010

20 Wittchen HU, "Generalized anxiety disorder : prevalence, burden, and cost to society" 16 : 162-171, 2002

21 National Institute for Health and Care Excellence: Guidelines, "Generalised anxiety disorder and panic disorder in adults: management" National Institute for Health and Care Excellence (NICE) 2019

22 Bandelow B, "Extended-release quetiapine fumarate(quetiapine XR) : a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo-and active-controlled study" 13 : 305-320, 2010

23 Baldwin DS, "Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder : a revision of the 2005 guidelines from the British Association for Psychopharmacology" 28 : 403-439, 2014

24 McEvoy PM, "Epidemiology of anxiety disorders in the Australian general population : findings of the 2007 Australian National Survey of Mental Health and Wellbeing" 45 : 957-967, 2011

25 Stein DJ, "Efficacy of agomelatine in generalized anxiety disorder : a randomized, double-blind, placebo-controlled study" 28 : 561-566, 2008

26 Stein DJ, "Efficacy and tolerability of extended release quetiapine fumarate(quetiapine XR)monotherapy in patients with generalised anxiety disorder : an analysis of pooled data from three 8-week placebo-controlled studies" 26 : 614-628, 2011

27 Moffitt TE, "Depression and generalized anxiety disorder : cumulative and sequential comorbidity in a birth cohort followed prospectively to age 32 years" 64 : 651-660, 2007

28 Andrews G, "Deconstructing current comorbidity : data from the Australian National Survey of Mental Health and Well-Being" 181 : 306-314, 2002

29 Wittchen HU, "DSM-III-R generalized anxiety disorder in the National Comorbidity Survey" 51 : 355-364, 1994

30 Meibach RC, "Comparative efficacy of propranolol, chlordiazepoxide, and placebo in the treatment of anxiety : a double-blind trial" 48 : 355-358, 1987

31 Crits-Christoph P, "Combined medication and cognitive therapy for generalized anxiety disorder" 25 : 1087-1094, 2011

32 Kessler RC, "Co-morbid major depression and generalized anxiety disorders in the National Comorbidity Survey follow-up" 38 : 365-374, 2008

33 Katzman MA, "Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders" 14 (14): S1-, 2014

34 Altamura AC, "Augmentative quetiapine in partial/nonresponders with generalized anxiety disorder : a randomized, placebo-controlled study" 26 : 201-205, 2011

35 Hoge EA, "Aripiprazole as augmentation treatment of refractory generalized anxiety disorder and panic disorder" 13 : 522-527, 2008

36 Menza MA, "An open-label trial of aripiprazole augmentation for treatment-resistant generalized anxiety disorder" 27 : 207-210, 2007

37 Rickels K, "Adjunctive therapy with pregabalin in generalized anxiety disorder patients with partial response to SSRI or SNRI treatment" 27 : 142-150, 2012

38 Pandina GJ, "Adjunctive risperidone in the treatment of generalized anxiety disorder : a double-blind, prospective, placebo-controlled, randomized trial" 40 : 41-57, 2007

39 Brawman-Mintzer O, "Adjunctive risperidone in generalized anxiety disorder : a double-blind, placebo-controlled study" 66 : 1321-1325, 2005

40 Mahableshwarkar AR, "A randomized, double-blind, fixed-dose study comparing the efficacy and tolerability of vortioxetine 2. 5 and 10 mg in acute treatment of adults with generalized anxiety disorder" 29 : 64-72, 2014

41 Khan A, "A randomized, double-blind study of once-daily extended release quetiapine fumarate(quetiapine XR)monotherapy in patients with generalized anxiety disorder" 31 : 418-428, 2011

42 Mahableshwarkar AR, "A randomised, double-blind, placebo-controlled, duloxetine-referenced study of the efficacy and tolerability of vortioxetine in the acute treatment of adults with generalised anxiety disorder" 68 : 49-59, 2014

43 Stein DJ, "12-week double-blind randomized multicenter study of efficacy and safety of agomelatine(25-50 mg/day)versus escitalopram(10-20 mg/day)in out-patients with severe generalized anxiety disorder" 28 : 970-979, 2018